

## 6. REFERENCIAS

1. Diccionario de la Lengua Española. Disponible en: URL: <https://dle.rae.es/>
2. Amin M, Edge S, Greene S, Byrd D, Bookland R, Wshintong M, et al. *AJCC Cancer Staging Manual*. 8ª edición. Nueva York: Springer; 2017.
3. Shah JP, Pate SGI. *Head and Neck Surgery and oncology*. 3ª edición. Missouri: Mosby Lt; 2003.
4. Oropharyngeal Cancer Treatment (PDQ®)—Health Professional Version. Disponible en: URL: <https://www.cancer.gov/types/head-and-neck/hp/adult/oropharyngeal-treatment-pdq>
5. Gunn B, Debnam M, Fuller C, Morrison W, Frank S, Beadle B, et al. The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. *Cancer*. 2013;19(17):3162-3169.
6. Silver C, Rubin JS. *Atlas of Head and Neck*. 2ª edición. Nueva York: Churchill Livingstone; 1999.
7. Harrinson L, Sessions RB, Hong W. *Head and Neck Cancer. A multidisciplinary approach*. Filadelfia: Lippincott Williams & Wilkins; 1998.
8. Anuario Epidemiológico. MPPS 2016. República Bolivariana de Venezuela. Disponible en: URL: <https://www.ovsalud.org/publicaciones/documentos-oficiales/boletin-epidemiologico-2016/>
9. Torres R, Nayelis N, Hernandez J, Perez-Cervera Y, Hernández-Antonio A, Argueta-Figueroa L. Reported epidemiology of cancer of the lip, oral cavity and oropharynx in Mexico. *Rev Med Inst Mex Seguro Soc*. 2020;58(4):494-507.
10. American Cancer Society: *Cancer Facts and Figures 2023*. Disponible en: URL: <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html>
11. Mendenhall WM, Werning JW, Pfister DG. *Treatment of head and neck cancer*. En: DeVita VT Jr, Lawrence TS, Rosenberg SA, editores. *Cancer: Principles and Practice of Oncology*. 9ª edición. Filadelfia: Lippincott Williams & Wilkins; 2011.
12. Choi WH, Hu KS, Culliney B, Kues M. *Cancer of the oropharynx*. En: Harrison LB, Sessions RB, Hong WK, editores. *Head and Neck Cancer: A Multidisciplinary Approach*. 3ª edición. Filadelfia: Lippincott William & Wilkins; 2009.
13. Fossum C, Chintakuntlawar A, Price DL, Garcia JJ. *Characterization of the oropharynx: Anatomy, histology, immunology, squamous cell carcinoma and surgical resection*. Disponible en: URL: <https://onlinelibrary.wiley.com/doi/full/10.1111/his.13140>
14. *Oral cavity and oropharynx*. En: Rosai J, editor. *Rosai and Ackerman's Surgical Pathology*. 10ª edición. Missouri: Mosby Elsevier; 2001.p.237-264.
15. Bryce M, Boysen M, Alfsen CG, A beler VM, Sudbø J, Nesland JM, et al. The invasive front of carcinomas. The most important area for tumour prognosis? *Anticancer Res*. 1998;18(6B):4757-4764.
16. Gillison ML, Koch WM, Capone RB, Spford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst*. 2000;92(9):709-720
17. Tabor MP, Braakhuis BJ, van der Wal JE, Leemans R, Van Diest P, Brakenhoff R, et al. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. *J Pathol*. 2023;199(3):354-360.
18. Castro S, Carvajal F, Cardemil F. Biopsia en carcinoma escamoso de orofaringe. *Rev Cir*. 2024;76(1). Disponible en: URL: <https://revistacirugia.cl/index.php/revistacirugia/article/view/1875> [Consultado 26 marzo 2024].
19. Mehanna H, Evans M, Beasley M, Chatterjee S, Dilkes M, Homer J, et al. *Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines*. *J Laryngol Otol*. 2016;130(S2):S90-96.
20. Rao RS, Ramakantha Chatura K, Sowmya Sv, Prasad K, Lakshminarayana S, Mukram Ali, et al. *Procedures and pitfalls in incisional biopsies of oral squamous cell*

- carcinoma with respect to histopathological diagnosis. *Dis Mon.* 2020;66(12):101035. doi: 10.1016/j.disamonth.2020.101035.
21. Raja R, Seethala JA, Bishop WC, Faquin WC, Hui Huang S, Katabi N, et al. Protocol for the examination of specimens from patients with carcinomas of the pharynx. USA: College of American Pathologists, 2023. Disponible en: URL: [https://documents.cap.org/protocols/HN.Pharynx\\_4.3.0.0.REL\\_CAPCP.pdf](https://documents.cap.org/protocols/HN.Pharynx_4.3.0.0.REL_CAPCP.pdf)
  22. Bishop JA, Lewis JS Jr, Rocco JW, Faquin WC. HPV-related squamous cell carcinoma of the head and neck: An update on testing in routine pathology practice. *Semin Diagn Pathol.* 2015;32(5):344-351.
  23. Maxwell, JH, Ferris, RL, Gooding W, Cunningham D, Mehta V, Myers K. Extracapsular spread in head and neck carcinoma: Impact of site and human papillomavirus status. En: Johnson J, Chiosea S, editors. *Cancer.* 2013.p.3302-3308.
  24. Chernock RD, Lewis JS. Approach to metastatic carcinoma of unknown primary in the head and neck: Squamous cell carcinoma and beyond. *Head Neck Pathol.* 2015;9(1):6-15.
  25. Boettiger BP, Rey D, Salazar I, Cristofer F, Marqués M, Zamorano SR. Metástasis cervical con primario desconocido, cambios en los paradigmas. Revisión sobre el enfrentamiento clínico, estudio y tratamiento. *Rev Otorrinolaringol Cir Cabeza Cuello.* 2020;80(3):367-375.
  26. Lewis JS Jr, Adelstein DJ, Agaimy A, Carlson DL, Faquin WC, Helliwell T, et al. Data set for the reporting of carcinomas of the nasopharynx and oropharynx: Explanations and recommendations of the Guidelines from the International Collaboration on Cancer Reporting. *Arch Pathol Lab Med.* 2019;143(4):447-451.
  27. Lewis Jr J, Beadle B, Bishop JA, Chernock R, Colasacco C, Lacchetti C, et al. Human papillomavirus testing in head and neck carcinomas: Guideline from the College of American Pathologists. *Arch Pathol Lab Med.* 2018;42(5): 559-597.
  28. Naha K, Biedermann G, Nada A, Cousins J, Layfield L, Schnabel J. Preoperative determination of depth of invasion in oral cavity squamous cell carcinoma by standard cross-sectional imaging with Computed Tomography and Positron Emission Tomography/Computed Tomography. *Cureus.* 2023;15(6):e40794.
  29. Parvathaneni U, Lavertu P, Gibson MK, Glastonbury C. Advances in diagnosis and multidisciplinary management of oropharyngeal squamous cell carcinoma: State of the art. *RadioGraphics.* 2019;39(7):2055-2068.
  30. Trotta BM, Pease CS, Raghavan P, Mukherjee S. Oral cavity and oropharyngeal squamous cell cancer: Key imaging findings for staging and treatment planning. *RadioGraphics.* 2011;31(2):339-354.
  31. Hudgins PA. Contrast enhancement in head and neck imaging. *Neuroimaging Clin N Am.* 1994;4(1):101-115.
  32. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017;67(1):7-30.
  33. Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. *J Clin Oncol.* 2015;33(8):836-845
  34. Applebaum KM, Furniss CS, Zeka A, Posner M, Smith JF, Bryan J, et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. *J Natl Cancer Inst.* 2007;99:1801-1810.
  35. Castro MS, Seguí VG, Contreras RJ, Cardemil M. Actualización en carcinoma escamoso orofaríngeo. *Rev Otorrinolaringol Cir Cabeza Cuello.* 2021;81(2):291-305.
  36. Loevner LA, Learned KO, Mohan S, O'Malley BW, Scanlon MH, Rassekh CH, et al. Transoral Robotic Surgery in head and neck cancer: What radiologists need to know about the cutting edge. *RadioGraphics.* 2013;33(6):1759-1779.
  37. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell J, et al. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw.* 2014;12:1454-1487.
  38. Aiken AH, Rath TJ, Anzai Y, Branstetter BF, Hoang JK, Wiggins RH, et al. ACR Neck Imaging Reporting and Data Systems (NI-RADS): A white paper of the ACR NI-RADS Committee. *J Am Coll Radiol.* 2018;15(8):1097-1108.
  39. Leung AS, Rath TJ, Hughes MA, Kim S, Branstetter BF. Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinoma. *Head Neck.* 2016;(Suppl 1):E853-E858
  40. Corey A. Pitfalls in the staging of cancer of the oropharyngeal squamous cell carcinoma. *Neuroimag Clin N Am.* 2013;(1):47-66.
  41. Chow LQM. Head and neck cancer. *N Engl J Med.* 2020;382(1):60-72.

42. Avery E, Josh, K, Mehra S, Mahajan A. Role of PET/CT in oropharyngeal cancers. *Cancer (Basell)*. 2023;15(9):2651.
43. Patel Y, Srivastava S, Divyesh R, Goel A, Suryanarayana K, Kumar Saini S. PET-CT scan-based maximum standardized uptake value as a prognostic predictor in oropharynx squamous cell cancer. *Cancer Treat Res Commun*. 2021;26:100305.
44. SJ Kim, K Pak, K Kim. Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients: A systematic review and meta-analysis. *Am J Otolaryngol*. 2019;40(2):297-305.
45. Tantiwongkosi B, Yu F, Kanard A, Miller FR. Role of (18) F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. *World J Radiol*. 2014;6(5):177-191.
46. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. *Radiology*. 2012;264(2):559-566.
47. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective risk-adjusted [18F]fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. *J Clin Oncol*. 2009;27(15):2509-2515.
48. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN guidelines insights: Head and neck cancers, version 1.2018. *J Natl Compr Canc Netw*. 2018;16(5):479-490.
49. Ping S, Steven D, Alamgeer M, Ganju V. Impact of pretreatment combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography staging on Radiation Therapy treatment decisions in locally advanced breast cancer. *Int J Radiat Oncol Biol Phys*. 2015;93:111-117.
50. Lowe VJ, Duan F, Subramaniam RM, Sicks JD, Romanoff J, Bartel T, et al. Multicenter Trial of [(18)F] fluorodeoxyglucose Positron Emission Tomography/Computed Tomography staging of head and neck cancer and negative predictive value and surgical impact in the N0 Neck: Results from ACRIN 6685. *J Clin Oncol*. 2019;37:1704-1712.
51. Shi X, Meng X, Sun X, Xing L, Yu J. PET/CT imaging-guided dose painting in radiation therapy. *Cancer Lett*. 2014;355(2):169-175.
52. Heukelom J, Hamming O, Bartelink H, Hoebbers F, Giralt J, Herlestam T, et al. Adaptive and innovative Radiation treatment for improving cancer treatment outcome (ARTFORCE): A randomized controlled phase II trial for individualized treatment of head and neck cancer. *BMC Cancer*. 2013;22:13-84.
53. Berwouts D, Madani I, Duprez F, Olteanu AL, Vercauteren T, Boterberg T, et al. Long-term outcome of (18) F-fluorodeoxyglucose-positron emission tomography-guided dose painting for head and neck cancer: Matched case-control study. *Head Neck*. 2017;39(11):2264-2275.
54. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. *Head Neck*. 2004;26(10):890-896.
55. Roman BR, Goldenberg D, Givi B, Education Committee of American Head and Neck Society (AHNS). AHNS Series-Do you know your guidelines? Guideline recommended follow-up and surveillance of head and neck cancer survivors. *Head Neck*. 2016;38(2):168-174.
56. Rabalais AG, Walvekar R, Nuss D, McWhorter A, Wood C, Fields R, et al. Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. *Laryngoscope*. 2009;119(6):1120-1124.
57. Roman BR, Patel SG, Wang MB, Pou AM, Holsinger FC, Myssiorek D, et al. Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. *J Natl Compr Canc Netw*. 2015;13(1):69-77.
58. Ho AS, Tsao GJ, Chen FW, Shen T, Kaplan MJ, Colevas AD, et al. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. *Cancer*. 2013;119(7):1349-1356.
59. Spector ME, Chinn SB, Rosko AJ, Worden FP, Ward PD, Divi V, et al. Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: ¿Are we changing life expectancy? *Laryngoscope*. 2012;122(7):1507-1511.
60. Villarreal Renedo P, García-Rozado González A, Cebrián Carretero JL. Biopsia de los ganglios centinelas cervicales en el carcinoma de células escamosas oral y orofaríngeo. *Protocolos clínicos de la Sociedad Española de Cirugía Oral y Maxilofacial*. Disponible en: URL: <https://www.secomcyc.org/wp-content/uploads/2014/01/cap38.pdf>
61. Garrel RA-OX, Poissonnet G, Moyà Plana A, Fakhry N, Dolivet G, Benjamin Lallemand B,

- et al. Randomized equivalence trial to compare treatment based on sentinel lymph node biopsy versus neck lymph node dissection in operable T1-T2N0 oral and oropharyngeal cancer. *J Clin Oncol.* 2020;38(34):4010-4018.
62. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17 346 patients. *Radiother Oncol.* 2009;92(1):4-14.
63. Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19 805 patients, on behalf of MACH-NC Group. *Radiother Oncol.* 2021;15:281-293.
64. Georges P, Rajagopalan K, Leon C, Singh P, Ahmad N, Nader K, et al. Chemotherapy advances in locally advanced head and neck cancer. *World J Clin Oncol.* 2014;5:966-972.
65. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. *Lancet Oncol.* 2011;12(2):153-159.
66. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med.* 2007;357(17):1695-1704.
67. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Eric Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med.* 2007;357(17):1705-1715.
68. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst.* 2009;101:498-506.
69. Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol.* 2005;23:8636-8645.
70. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert HG, Pajak TF, et al. Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in 4 patients with locally advanced larynx cancer. *J Clin Oncol.* 2013;31:845-852.
71. Adelstein DJ, Li Y, Adams GL, Wagner Jr H, Kish JA, Ensley J, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol.* 2003;21(1):92-98.
72. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol.* 2010;11:21-28.
73. Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: A phase III randomized noninferiority trial. *J Clin Oncol.* 2018;36(11):1064-1072.
74. Burtneß B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro Jr G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE048): A randomised, open-label, phase 3 study. *Lancet.* 2019;394(10212):1915-1928.
75. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam M, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. *J Clin Oncol.* 2009;27:242-249.
76. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med.* 2008;359:1116-1127.
77. Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozeret H, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group Phase II study. *Cancer Invest.* 2007;25:182-188.
78. Gibson MK, Li Y, Murphy B, Hussain M, DeConti R, John Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395):

- An Intergroup Trial of the Eastern Cooperative Oncology Group. *J Clin Oncol*. 2005;23:3562-3567.
79. Burtneß B, Goldwasser MA, Flood W, Mattar B, Forastiere A, Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study. *J Clin Oncol*. 2005;23:8646-8654.
  80. Chan AT, Hsu MM, Goh BC, Hui E, Tsang-Wu Liu, Millward M, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. *J Clin Oncol*. 2005;23:3568-3576.
  81. Jin Y, Cai XY, Shi YX, Xi-Ya Xia, Yu-Chen Cai, Ye Cao, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. *J Cancer Res Clin Oncol*. 2012;138(10):1717-1725.
  82. Zhang L, Huang Y, Hong S, Yang Y, Gengsheng Yu, Jun Jia, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomised, open-label, phase 3 trial. *Lancet*. 2016;388:1883-1892.
  83. Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol*. 1992;10:257-263.
  84. Grau JJ, Caballero M, Verger E, Monzó M, Blanch J. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. *Acta Otolaryngol*. 2009;129:1294-1299.
  85. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. *Ann Oncol*. 1994;5:533-537.
  86. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. *Eur J Cancer*. 2004;40:2071-2076.
  87. Stewart JS, Cohen EE, Licitra L, Khorprasert C, Soulieres D, Vodvarka P, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. *J Clin Oncol*. 2009;27:1864-1871.
  88. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. *J Clin Oncol*. 1992;10:1245-1251.
  89. Martinez-Trufero J, Isla D, Adansa JC, Hitt R, Gil-Arnaiz I, Lamba J, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. *Br J Cancer*. 2010;102:1687-1691.
  90. Zhang Y, Huang PY, Fei Xu, Pei-Jian Peng, Zhong-Zhen Guan et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. *Cancer Chemother Pharmacol*. 2008;61:33-38.
  91. Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2016;375:1856-1867.
  92. Seiwert TY, Burtneß B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicenter, phase 1b trial. *Lancet Oncol*. 2016;17:956-965.
  93. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase 1b KEYNOTE-012 expansion cohort. *J Clin Oncol*. 2016;34:3838-3845.
  94. Hsu C, Lee SH, Ejadi S, Even C, Cohen R, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. *J Clin Oncol*. 2017;35:4050-4056.
  95. Machiels JP, Haddad RI, Fayette J, Licitra L, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. *Lancet Oncol*. 2015;16:583-594.

96. Psyrri A, Rampias T, Vermorken JB. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of head and neck. *Ann Oncol.* 2014;25(11):2101-2115.
97. Mehanna H, Rischin D, Wong S, Gregoire V, Ferris R, Waldron J, et al. De-escalation after De-Escalate and RTOG 1016: A Head and Neck Cancer InterGroup FramaWork for future de-escalation studies. *J Clin Oncol.* 2020;38(22):2552-2557.
98. Kofler B, Laban S, Busch CJ, Lörincz B, Knecht R. New treatment strategies for HPV-positive head and neck cancer. *Eur Arch Otorhinolaryngol.* 2014;271(7):1861-1867.
99. Adelstein DJ, Ridge J, Brizel DM, Holsinger C, Haughey B, O'Sullivan B, et al. Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting. *Head Neck.* 2012;34(12):1681-1703.
100. Li RJ, Richmon J. Transoral endoscopic surgery: New surgical techniques for oropharyngeal cancer. *Otolaryngol Clin North Am.* 2012;45:823-844.
101. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. *Lancet Oncol.* 2019;20:1349-1359.
102. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: Long-term results of the ORATOR trial. *J Clin Oncol.* 2022;40:866-875.
103. Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, et al. Assessment of toxic effects and survival in treatment de-escalation with radiotherapy versus transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: The ORATOR 2 phase 2 randomized clinical trial. *JAMA Oncol.* 2022;8(6):1-7.
104. Silver JA, Turkdogan S, Roy CF, Subramaniam T, Henry M, Sadeghi N. De-Escalation strategies for human papillomavirus-associated oropharyngeal squamous cell carcinoma--Where are we now? *Curr Oncol.* 2022;29:3668-3697.
105. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med.* 2010;363(1):24-35.
106. Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). *J Clin Oncol.* 2022;40(2):138-149.
107. Miles BA, Posner MR, Gupta V, Teng MS, Bakst RL, Yao M, et al. De-Escalated adjuvant therapy after transoral robotic surgery for human papillomavirus-related oropharyngeal carcinoma: The Sinai Robotic Surgery (SIRS) Trial. *Oncologist.* 2021;26(6):504-513.
108. Marur S, Li S, Cmelak A, Gillison M, Zhao W, Ferris R, et al. E1308: Phase II trial of induction chemotherapy followed by reduce-dose radiation weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group. *J Clin Oncol.* 2017;5:490-497.
109. Ma DJ, Price K, Moore E, Patel S, Hinni M, Garcia JJ, et al. Phase II evaluation aggressive dose de-escalation of adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. *J Clin Oncol.* 2019;37:1909-1918.
110. Yom SS, Torres-Saavedra P, Caudell J, Waldron J, Gillison M, Xia P, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). *J Clin Oncol.* 2021;39:956-965.
111. Chera BS, Amdur R, Green R, Shen C, Gupta G, Tan X, et al. Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma. *J Clin Oncol.* 2019;37(29):2661-2669.
112. Chen AM, Felix C, Wang P, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: A single arm, phase 2 study. *Lancet Oncol.* 2017;18(6):803-811.
113. Garden A, Kies MS, Morrison WH, Weber RS, Frank SJ, Glisson BS, et al. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21<sup>st</sup> century. *Radiat Oncol.* 2013;8:21.
114. Al-Mangani A, Van Rooij P, Tans L, Teguh D, Levendag PC. Toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer: A matched-pair analysis. *Technol Cancer Res Treat.* 2013;12:123-130.
115. Sher DJ, Adelstein D, K Bajaj G, Brizel D, Cohen E, Halthore A, et al. Radiation therapy for oropharyngeal

- squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical practice Guideline. *Pract Radiat Oncol.* 2017;7:246-253.
116. Eisbruch A, Harris J, Garden A, Chao CK, Straube W, Harari P, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). *Int J Radiat Oncol Biol Phys.* 2010;76:1333-1338.
117. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans C, Geoffrois L, et al. EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs. alternating chemotherapy and radiotherapy. *J Natl Cancer Inst.* 2009;101(3):142-152.
118. Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias J, et al. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. *Radiother Oncol.* 2021;156:281-293.
119. Michal SA, Adelstein DJ, Rybicki LA, Rodriguez CP, Saxton JP, Wood BG, et al. Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. *Head Neck.* 2012;34(8):1147-1152.
120. Geoffrois L, Martin L, De Raucourt D, Sun X, Tao Y, Maingon P, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. *J Clin Oncol.* 2018;36(31):3077-3083.
121. Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, et al. Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. *Ann Oncol.* 2014;25(1):216-225.
122. Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, et al. GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. *Ann Oncol.* 2017;28(9):2206-2212.
123. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. *J Clin Oncol.* 2014;32(25):2735-2743.
124. Bots WT, van den Bosch S, Zwijnenburg EM, Dijkema T, B van den Broek G, J Weijs W, et al. Reirradiation of head and neck cancer: Long-term disease control and toxicity. *Head Neck.* 2017;39(6):1122-1130.
125. Rudzianskas V, Kupcinskaite-Noreikiene R, Inciura A, Juozaityte E, Rudzianskiene M, Kubilius R, et al. Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy. *Acta Otorhinolaryngol Ital.* 2012;32(5):297-303.
126. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. *Int J Radiat Oncol Biol Phys.* 2009;73(2):399-409.
127. Lee J, Kim WC, Yoon WS, Koom WS, Rim CH. Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer: A meta-analysis and systematic review. *Oral Oncology.* 2020;107:104757.
128. Lee N, Chan K, Bekelman J, Zhung J, Mechalakos J, Narayana A, et al. Salvage Re-Irradiation for Recurrent Head and Neck Cancer. *Int J Radiat Oncol Biol Phys.* 2007;68(3):731-740.
129. Lee A, Woods R, Mahfouz A, Kitpanit S, Cartano O, Mohamed N, et al. Evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell carcinoma. *JAMA Netw Open.* 2023;6(1):e2250607.
130. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimes in unresected locally advanced squamous cell carcinoma of the head and neck. *BMC Cancer.* 2006;6:28.
131. Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6Gy alone in locally advanced head and neck cancer: Long terms results of the ARO 95-06 randomized phase III trial. *Int J Radiat Oncol Biol Phys.* 2015;91:916-924.
132. Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head

- and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. *Lancet Oncol.* 2012;13:145-153.
133. Haigentz M, Corry J, Strojan P, Ferlito A. Easing acceleration of head and neck chemoradiotherapy. *Lancet Oncol.* 2012;13:113-115.
  134. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. *Lancet Oncol.* 2019;20:1349-1359.
  135. Ang K, Zhang Q, Wheeler RH, Rosenthal D, Nguyen-Tan F, Kim C, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. Disponible en: URL: [https://ascopubs.org/doi/10.1200/jco.2010.28.15\\_suppl.5507](https://ascopubs.org/doi/10.1200/jco.2010.28.15_suppl.5507)
  136. Nguyen-Tan PF, Zhang Q, Ang KK, Weber R, Rosenthal D, Soulieres D, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trail: Long-term report of efficacy and toxicity. *J Clin Oncol.* 2014;32:3858-3866.
  137. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radio chemotherapy in advanced-stage oropharynx carcinoma. *J Clin Oncol.* 2004;22:69-76.
  138. Bourhis J, Calais G, Lapeyre M, Tortochaux T, Alfonsi M, Sire C, et al. Concomitant radiochemotherapy or accelerated radiotherapy: Analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). *Semin Oncol.* 2004;31:822-826.
  139. Machtay M, Moughan J, Trotti A, Garden A, Weber R, Jay S, Cooper J, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. *J Clin Oncol.* 2008;26:3582-3589.
  140. Bonner JA, Harari P, Giralt J, Azarnia N, Shin D, Cohen R, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med.* 2006;354(6):567-578.
  141. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (DE-ESCALATE HPV): An open-label randomised controlled phase 3 trial. *Lancet.* 2019;393(10166):51-60.
  142. Gillison ML, Trotti A, Harris J, Eisbruch A, Harari P, Adelstein D, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG1016): A randomised, multicenter, non-inferiority trial. *Lancet.* 2019;393:40-50.
  143. Johrens K, Keiholz U, Kaufmann A, Lehmann A, Weichert W, Stenzinger A, et al. Contribution of human papillomavirus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. *Eur J Cancer.* 2015;51(4):514-521.
  144. De Virgilio A, Costantino A, Mercante G, Petruzzi G, Sebastiani D, Franzese C, et al. Present and future of de-intensification strategies in the treatment of oro-pharyngeal carcinoma. *Curr Oncol Rep.* 2020;22(9):91.
  145. De Virgilio A, Costantino A, Mercante G, Pellini R, Ferrel F, Malvezzi L, et al. Transoral robotic surgery and intensity-modulated radiotherapy in the treatment of the oropharyngeal carcinoma: A systematic review and meta analysis. *Eur Arch Otorhinolaryngol.* 2021;278(5):1321-1335.
  146. Weinstein GS, O'Malley BW, Snyder W, Sherman E, Quon H. Transoral robotic surgery: Radical tonsillectomy. *Arch Otolaryngol Head Neck Surg.* 2007;133(12):1220-1226.
  147. Moore EJ, Hinni ML. Critical review: Transoral laser microsurgery and robotic-assisted surgery for oropharynx cancer including human papillomavirus-related cancer. *Int J Radiat Oncol Biol Phys.* 2013;85:1163-1167.
  148. Bernal M, Blanch J, Vilaseca I, Steiner W, Ambrosch P. 2004. Cirugía con Láser CO<sub>2</sub> en la vía aerodigestiva superior. Disponible en: URL: <https://es.slideshare.net/aderitodesousa/bernal-llibre2>
  149. Castro SM, Segui V, Contreras J, Felipe Cardemil F. Actualización en carcinoma escamoso de orofaringe. *Rev Otorrinolaringol Cir Cabeza Cuello.* 2021;81:291-305.
  150. Remmler D, Medina JE, Byers RM, Meoz R, Pfalzgraf K. Treatment of choice for squamous carcinoma of the tonsillar fossa. *Head Neck Surg.* 1985;7(3):206-211.
  151. Ballantyne AJ Principles of Surgical management of cancer of pharyngeal walls. *Cancer.* 1967;20:663-667.
  152. Malik A, Hardmann J, Devabalan Y, Nutting C, Bhide S, Harrington K, et al. Systematic review and meta-

- analysis of occult contralateral nodal metastases in patients with oropharyngeal squamous carcinoma undergoing elective neck dissection. *Eur J Surg Oncol.* 2023;49(2):316-322
153. Mijares Briñez A, Suarez CM, Franco A, Pérez D, Diaz K, Mujica N. Cirugía Robótica Oncológica Transoral: Reporte del primer caso en Venezuela. *Rev Venez Oncol.* 2023;35(1):65-71.
  154. Persky MJ, Albergotti WG, Rath TJ, Kubik MW, Abberbock S, Geltzeiler M, et al. Positive margins by oropharyngeal subsite in transoral robotic surgery for T1/T2 squamous cell carcinoma. *Otolaryngol Head Neck Surg.* 2018;158(4):660-666.
  155. Hanna J, Morse E, Brauer PR, Judson B, Mehra S. Positive margin rates and predictors in transoral robot surgery after federal approval: A national quality study. *Head Neck.* 2019;41:3064-3072
  156. de Almeida JR, Li R, Magnuson JS, Smith RV, Moore E, Lawson G, et al. Oncologic Outcomes After Transoral Robotic Surgery. *JAMA Otolaryngol Head Neck Surg.* 2015;141:1043-1051.
  157. Baskin RM, Boyce BJ, Amdur R, Mendenhall WM, Hitchcock K, Silver N, et al. Transoral robotic surgery for oropharyngeal cancer: Patient selection and special considerations. *Cancer Manag Res.* 2018;10:839-846.
  158. Gaino F, Gorphe P, Vander Poorten V, Holsinger FC, Lira RB, Duvvuri U, et al. Preoperative predictors of difficult oropharyngeal exposure for transoral robotic surgery: The pharyngoscore. *Head Neck.* 2021;43:3010-3021.
  159. Bollig CA, Gilley DR, Ahmad J, Jorgensen JB. Prophylactic arterial ligation following transoral robotic surgery: A systematic review and meta-analysis. *Head Neck.* 2020;42:739-746.
  160. Turner MT, Stokes WA, Stokes CM, Hassid S, Holsinger FC, Lawson G. Airway and bleeding complications of transoral robotic supraglottic laryngectomy (TORS-SGL): A systematic review and meta-analysis. *Oral Oncol.* 2021;118:105301.
  161. Stokes W, Ramadan J, Lawson G, Ferris FRL, Holsinger FC, Turner MT. Bleeding complications after transoral robotic surgery: A meta-analysis and systematic review. *Laryngoscope.* 2021;131:95-105.
  162. Parhar HS, Gausden E, Patel J, Prisman E, Anderson DW, Durham JS, et al. Analysis of readmissions after transoral robotic surgery for oropharyngeal squamous cell carcinoma. *Head Neck.* 2018;40:2416-2423.
  163. Carpentier C, Bobillier C, Blanchard D, Lallemand B, Garrel R, Gorphe P, et al. Spondylodiscitis after transoral robotic surgery: Retrospective 7-case series from the GETTEC group. *Eur Ann Otorhinolaryngol Head Neck Dis.* 2019;136:179-183.
  164. Sethi RKV, Chen MM, Malloy KM. Complications of Transoral Robotic Surgery. *Otolaryngol Clin N Am.* 2020;53:1109-1115.
  165. Aubry K, Vergez S, de Mones E, Moriniere S, Choussy O, Malard O, et al. Morbidity and mortality revue of the French group of transoral robotic surgery: A multicentric study. *J Robot Surg.* 2016;10:63-67.
  166. Park YM, Kim DH, Kang MS, Lim JY, Choi EC, Koh YW, et al. The first human trial of transoral robotic surgery using a single-port robotic system in the treatment of laryngo-pharyngeal cancer. *Ann Surg Oncol.* 2019;26:4472-4480.
  167. Sampieri C, Costantino A, Pirola F, Kim D, Lee K, Kim SH. Neoadjuvant chemotherapy combined with transoral robotic surgery for stage III and IV laryngeal and hypopharyngeal carcinomas. *Oral Oncol.* 2023;140:106371.
  168. Solimeno LS, Park YM, Lim JY, Koh YW, Kim SH. Treatment outcomes of neoadjuvant chemotherapy and transoral roboticsurgery in locoregionally advanced laryngopharyngeal carcinoma. *Head Neck.* 2021;43(11):3429-3436.
  169. Tateya I, Shiotani A, Satou Y, Tomifuji M, Morita S, Muto M, et al. Transoral surgery for laryngopharyngeal cancer - The paradigm shift of the head and cancer treatment. *Auris Nasus Larynx.* 2016;43:21-32.
  170. Golusiński W, Golusińska-Kardach E. Current role of surgery in the management of oropharyngeal cancer. *Front Oncol.* 2019;9:388.
  171. Turner MT, Byrd JK, Ferris RL. Current Role of surgery in the management of oropharyngeal cancer. *J Oncol Pract.* 2016;2(11):1176-1183.
  172. Qureshi HA, Abouyared M, Barber B, Houlton JJ. Surgical options for locally advanced oropharyngeal cancer. *Curr Treat Options Oncol.* 2019;20(5):36.
  173. Hay A, Nixon IJ. Recent advances in the understanding and management of oropharyngeal cancer. *F1000Res.* 2018;7:F1000.
  174. O'Malley BW Jr, Weinstein GS, Hockstein NG. Transoral robotic surgery (TORS): Glottic microsurgery in a canine model. *J Voice.* 2006;20(2):263-268.
  175. Chen J, Zhang X, Yan S, Li X, Li M, Zhang Y, et al. Transoral robotic surgery and human papillomavirus infection: Impact on oropharyngeal cancer prognosis. *J Clin Med.* 2024;13(15):4455.

176. Baskin RM, Boyce BJ, Amdur R, Mendenhall WM, Hitchcock K, Silver N, et al. Transoral robotic surgery for oropharyngeal cancer: Patient selection and special considerations. *Cancer Manag Res*. 2018;10:839-846.
177. Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2020;18(7):873-898.
178. Tsai MH, Cheng YJ, Pao TH, Hsueh WT, Chen HHW, Wu YH. Association of primary treatment modality for advanced-stage oropharyngeal squamous cell carcinoma with survival outcomes. *JAMA Netw Open*. 2021;4(6):e2112067.
179. Hussain T, Thangavelu K, Kürten C, Galland L, Höing B, Deuss E, et al. The accuracy of clinical neck staging for p16-positive and negative oropharyngeal cancer and its therapeutic implications. *Eur Arch Otorrinolaringol*. 2022;279(11):5339-5345.
180. Schouten CS, de Graaf P, Alberts FM, Hoekstra OS, Comans EF, Bloemena E, et al. Response evaluation after chemoradiotherapy for advanced nodal disease in head and neck cancer using diffusion-weighted MRI and 18F-FDG-PET-CT. *Oral Oncol*. 2015;51:541-547.
181. Faraji F, Coquia SF, Wenderoth MB, Padilla ES, Blitz D, DeJong MR, et al. Evaluating oropharyngeal carcinoma with transcervical ultrasound, CT, and MRI. *Oral Oncol*. 2018;78:177-185.
182. Muylle K, Castaigne C, Flamen P. 18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: Recent developments in head and neck cancer. *Curr Opin Oncol*. 2005;17:249-253.
183. Tahari AK, Alluri KC, Quon H, Koch W, Wahl RL, Subramaniam RM. FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: Characteristics of human papillomavirus-positive and -negative tumors. *Clin Nucl Med*. 2014;39:225-231.
184. Golusinski W. The role of conventional surgery in oropharyngeal cancer. *Recent Results Cancer Res*. 2017;206:185-195.
185. Ford SE, Brandwein-Gensler M, Carroll WR, Rosenthal EL, Magnuson JS. Transoral robotic versus open surgical approaches to oropharyngeal squamous cell carcinoma by human papillomavirus status. *Otolaryngol. Head Neck Surg*. 2014;151:606-611.
186. Liederbach E, Lewis CM, Yao K, Brockstein BE, Wang CH, Lutfi W, et al. Contemporary analysis of surgical trends in the treatment of squamous cell carcinoma of the oropharynx from 1998 to 2012: A Report from the National Cancer Database. *Ann Surg Oncol*. 2015;22:4422-4431.
187. Moore EJ, Olsen SM, Laborde RR, García JJ, Walsh FJ, Price DL. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. *Mayo Clin Proc*. 2012;87:219-225.
188. Hutcheson KA, Holsinger FC, Kupferman ME, Lewin JS. Functional outcomes after TORS for oropharyngeal cancer, a systematic review. *Eur Arch Otorhinolaryngol*. 2015;272:463-471.
189. Gleich LL, Ryzenman J, Gluckman JL, Wilson KM, Barrett WL, Redmond KP. Recurrent advanced (T3 or T4) head and neck squamous cell carcinoma: Is salvage possible? *Arch Otolaryngol Head Neck Surg*. 2004;130(1):35-38.
190. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: When do the ends justify the means? *Laryngoscope*. 2000;110(3Pt2 Suppl 93):S1-18.
191. Agra IM, Carvalho AL, Ulbrich FS, de Campos OD, Martins EP, Magrin J, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. *Head Neck*. 2006;28:107-113.
192. Zafereo ME, Hanasono MM, Rosenthal DI, Sturgis EM, Lewin JS, Roberts DB, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. *Cancer*. 2009;115:5723-5733.
193. Patel SN, Cohen MA, Givi B, Dixon BJ, Gilbert RW, Gullane PJ, et al. Salvage surgery for locally recurrent oropharyngeal cancer. *Head Neck*. 2016;38 (Suppl 1):E658-664.
194. White R, Abel S, Hasan S, Verma V, Greenberg L, Colonias A, et al. Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer. *Laryngoscope*. 2020;130(4):E171-E176.
195. Sweeny L, Rosenthal EL, Clemons L, Stevens TM, Cook McIntosh ER, Carroll WR. Outcomes after surgical salvage for recurrent oropharyngeal squamous cell carcinoma. *Oral Oncol*. 2016;60:118-124.
196. Santoro L, Tagliabue M, Massaro MA, Ansarin M, Calabrese L, Giugliano G, et al. Algorithm to predict postoperative complications in oropharyngeal and oral cavity carcinoma. *Head Neck*. 2015;37:548-556.

197. Gullane PJ. Changing concepts in soft tissue repair of oral and oropharyngeal defects. *Arch Otolaryngol Head Neck Surg.* 2000;126(7):912-913.
198. Zafereo ME, Weber RS, Lewin JS, Roberts OB, Hanasono MM. Complications and functional outcomes following complex oropharyngeal reconstruction. *Head Neck.* 2010;32(8):1003-1011.
199. Vartanian JG, Carvalho AL, Carvalho SM, Mizobe L, Magrin J, Kowalski LP. Pectoralis major and other myofascial and myocutaneous flaps in head and neck cancer reconstruction: Experience with 437 cases at a single institution. *Head Neck.* 2004;26(12):1018-1023.
200. Sabri A. Oropharyngeal reconstruction: Current state of the art. *Curr Opin Otolaryngol Head Neck Surg.* 2003;11(4):251-254.
201. Smith JE, Oucic Y, Adelson R. The utility of the temporalis muscle flap for oropharyngeal, base of tongue, and nasopharyngeal reconstruction. *Otolaryngol Head Neck Surg.* 2005;132(3):373-380.
202. Deleyiannis FW, Rogers C, Lee E, Russavage J, Gastman B, Dunklebarger J, et al. Reconstruction of the lateral mandibulectomy defect: Management based on prognosis and location and volume of soft tissue resection. *Laryngoscope.* 2006;116(11):2071-2080.
203. Hanasono MM, Weinstock VE, Yul P. Reconstruction of extensive head and neck defects with multiple simultaneous free flaps. *Plast Reconstr Surg.* 2008;122(6):1739-1746.
204. Hanasono MM, Zevallos JP, Skoracki RJ, Yu P. A prospective analysis of bony versus soft-tissue reconstruction for posterior mandibular defects. *Plast Reconstr Surg* 2010;125(5):1413-1421.
205. Molteni G, Gazzini L, Sacchetto A, Nocini R, Comini LV, Arietti V, et al. Mandibular reconstruction in head and neck cancer: Which is the gold standard? *Eur Arch Otorhinolaryngol.* 2023;280(9):3953-3965.
206. Jewer DD, Boyd JB, Manktelow RT, Zuker RM, Rosen IB, Gullane PJ, et al. Orofacial and mandibular reconstruction with the iliac crest free flap: A review of 60 cases and a new method of classification. *Plast Reconstr Surg.* 1989;84(3):391-403.
207. Canis M, Plüquet S, Ihler F, Matthias C, Kron M, Steiner W. Impact of elective neck dissection vs. observation on regional recurrence and survival in cN0-staged patients with squamous cell carcinomas of the upper aerodigestive tract. *Arch Otolaryngol Head Neck Surg.* 2012;138(7):650-655.
208. Knewitz A, Nanda N, Hoffman MR, Dailey SH, Wieland AM, McCulloch TM. Pre-tracheotomy for potentially emergent airway scenarios: Indications and outcomes. *Laryngoscope.* 2021;131(11):E2802-E2809.
209. Talwar B, Findlay M. When is the optimal time for placing a gastrostomy in patients undergoing treatment for head and neck cancer? *Curr Opin Support Palliat Care.* 2012;6(1):41-53.
210. Brown TE, Spurgin AL, Ross L, Tripcony L, Keller J, Hughes BG, et al. Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy. *Head Neck.* 2013;35(10):1385-1391.
211. Din-Lovinescu C, Barinsky GL, Povolotskiy R, Grube JG, Park CW. Percutaneous endoscopic gastrostomy tube timing in head and neck cancer surgery. *Laryngoscope.* 2023;133(1):109-115.